Sponsors (2)
The bill is designed to speed patient access to biosimilars and reduce regulatory duplication by expanding mutual recognition, remote assessments, and clearer guidance—but it trades faster approvals and lower inspection burdens for increased legal, safety, privacy, and short-term implementation risks that must be managed.
Patients with chronic conditions and other drug users could get faster access to biosimilar medicines and face fewer supply disruptions because FDA would target inspections by risk, resolve inspection issues earlier in review, and use remote/alternative tools to speed reviews.
Hospitals, health systems, and the FDA could avoid duplicative or delayed inspections and approvals because greater use of mutual recognition agreements (MRAs), trusted foreign partners, and virtual expert interactions can streamline oversight.
Biologic manufacturers, biosimilar sponsors, and health systems may face lower regulatory delays and fewer redundant inspections—reducing time-to-market and some compliance burdens—if FDA relies more on MRAs and remote assessments.
Patients and health systems could face increased drug-quality and safety risks if greater reliance on foreign MRAs or remote inspections leads to gaps in oversight or misses issues that in-person inspections would catch.
Implementing expanded MRA programs, remote inspection systems, and new inspection plans will impose administrative, IT, and training costs on FDA and manufacturers during the transition, increasing short-term expenses for the agency, taxpayers, and some firms.
Expanded remote assessments and increased electronic information exchange raise cybersecurity, data privacy, and confidentiality risks for manufacturers and patients if data handling and protections are not strengthened.
Based on analysis of 5 sections of legislative text.
Directs FDA to expand use of MRAs and remote regulatory assessments and to publish a report and a one-year strategic plan to modernize biosimilar establishment inspections.
Official title: Improve the inspections of drug establishments engaged in the manufacture, preparation, propagation, or processing of biosimilar biological products conducted by the Food and Drug Administration, and for other purposes.
Introduced December 16, 2025 by Theodore Paul Budd · Last progress December 16, 2025
Requires the HHS Secretary (through FDA) to modernize how FDA inspects facilities that make biosimilar biological products by exploring and expanding use of mutual recognition agreements (MRAs), remote regulatory assessments, and other alternative inspection tools. It directs a public meeting and report on MRAs within 180 days, mandates updates to inspection processes to use a risk-based, remote-first approach, and requires a one-year strategic plan to address staffing, inspection challenges, and communications with biosimilar sponsors.